| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | ABBV | Common stock, $0.01 par value | Tax liability | -$5.42M | -35.1K | -37.72% | $154.28 | 58K | Feb 28, 2023 | Direct | |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$4.19M | -27.4K | -47.25% | $153.08 | 30.6K | Mar 1, 2023 | Direct | F1 |
| transaction | ABBV | Common stock, $0.01 par value | Sale | -$2.57M | -16.7K | -54.76% | $153.62 | 13.8K | Mar 1, 2023 | Direct | F2 |
| Id | Content |
|---|---|
| F1 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.37 to $153.36, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| F2 | The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $153.37 to $154.13, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
The option exercise and sale transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).